Is AbbVie stock a buy right now?

Is AbbVie stock a buy right now?

Still worth buying Second, AbbVie looks attractively valued at the moment with a forward price-to-earnings (P/E) ratio of 10.9, compared to an average of 12.8 for the pharmaceutical industry. Third, AbbVie is an excellent stock for dividend-seeking investors.

Is AbbVie a buy Zacks?

– Sell. Zacks’ proprietary data indicates that AbbVie Inc. is currently rated as a Zacks Rank 5 and we are expecting a below average return from the ABBV shares relative to the market in the next few months.

Is AbbVie a good long term buy?

Summary. AbbVie has reported solid quarterly results, with no major surprises. The company’s Humira patent expiry in the US is an upcoming headwind but should be manageable. Thanks to a high dividend yield, not a lot of growth is required for AbbVie to be a good long-term investment.

What is the target price for AbbVie?

Stock Price Target

High	$200.00
Low	$135.00
Average	$163.67
Current Price	$153.80

How high will AbbVie go?

The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 160.00, with a high estimate of 200.00 and a low estimate of 135.00. The median estimate represents a +4.85% increase from the last price of 152.60.

Is AbbVie a Buy Sell or Hold?

AbbVie Inc (ABBV) Shares are consolidating with a buy point at 176.01, according to MarketSmith.com. AbbVie stock has an IBD Digital Composite Rating of 95 out of a best-possible 99. The CR measures a stock’s key growth metrics.

What is AbbVie PE ratio?

The Bottom Line On AbbVie’s P/E Ratio AbbVie has a P/E of 39.8. That’s higher than the average in its market, which is 18.4.

Is ABBV a blue chip stock?

AbbVie. AbbVie (ABBV, $76.95) is another blue-chip pharma stock and the owner of Humira, the world’s No. 1 selling prescription drug.

Where will AbbVie stock be in 5 years?

Based on our forecasts, a long-term increase is expected, the “ABBV” stock price prognosis for 2027-06-30 is 301.377 USD. With a 5-year investment, the revenue is expected to be around +95.79%. Your current $100 investment may be up to $195.79 in 2027. Get It Now!

Does AbbVie pay a dividend?

(NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable May 16, 2022 to stockholders of record at the close of business on April 15, 2022. Since the company’s inception in 2013, AbbVie has increased its dividend by more than 250 percent.

Is Pfizer going to split?

Pfizer announced on 29 July that it will split off its Upjohn off-patent branded and generics business and merge it with Mylan NV to establish a top generic drug company, with $19bn to $20bn in pro forma 2020 revenues.

Is Johnson and Johnson a good stock to buy?

Shares of J&J have an Investor’s Business Daily Composite Rating of 95 out of a best-possible 99. The CR scores a stock’s key growth metrics against all other stocks regardless of industry group. So in terms of key growth measures, JNJ stock outranks 95% of all stocks.

How many shares does AbbVie have?

Share Statistics

Avg Vol (3 month) 3	7.34M
Shares Outstanding 5	1.77B
Implied Shares Outstanding 6	N/A
Float 8	1.77B
% Held by Insiders 1	0.11%

Is AbbVie stock going to split?

AbbVie (ABBV) has 0 splits in our AbbVie stock split history database.

Will AbbVie raise dividends in 2021?

(NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable August 16, 2021 to stockholders of record at the close of business on July 15, 2021. Since the company’s inception in 2013, AbbVie has increased its dividend by 225 percent.

What is the next ex-dividend date for AbbVie 2021?

ABBV Dividend History

Ex/EFF DATE	TYPE	PAYMENT DATE
01/13/2022	CASH	02/15/2022
10/14/2021	CASH	11/15/2021
07/14/2021	CASH	08/16/2021
04/14/2021	CASH	05/14/2021